ABEO | IVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 86 | |
P/E GROWTH RATING 1..100 | 76 | 100 | |
SEASONALITY SCORE 1..100 | 9 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABEO's Valuation (58) in the Pharmaceuticals Generic industry is somewhat better than the same rating for IVA (95) in the null industry. This means that ABEO’s stock grew somewhat faster than IVA’s over the last 12 months.
ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as IVA (100) in the null industry. This means that ABEO’s stock grew similarly to IVA’s over the last 12 months.
ABEO's SMR Rating (98) in the Pharmaceuticals Generic industry is in the same range as IVA (100) in the null industry. This means that ABEO’s stock grew similarly to IVA’s over the last 12 months.
ABEO's Price Growth Rating (63) in the Pharmaceuticals Generic industry is in the same range as IVA (86) in the null industry. This means that ABEO’s stock grew similarly to IVA’s over the last 12 months.
ABEO's P/E Growth Rating (76) in the Pharmaceuticals Generic industry is in the same range as IVA (100) in the null industry. This means that ABEO’s stock grew similarly to IVA’s over the last 12 months.
| ABEO | IVA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 82% |
| Momentum ODDS (%) | N/A | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 87% |
| Advances ODDS (%) | 12 days ago 83% | 6 days ago 76% |
| Declines ODDS (%) | 5 days ago 84% | 10 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 72% | 1 day ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABEO’s FA Score shows that 0 FA rating(s) are green while IVA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABEO’s TA Score shows that 4 TA indicator(s) are bullish while IVA’s TA Score has 5 bullish TA indicator(s).
ABEO (@Biotechnology) experienced а -6.85% price change this week, while IVA (@Biotechnology) price change was +5.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.
ABEO is expected to report earnings on Nov 16, 2026.
IVA is expected to report earnings on Nov 23, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XC | 30.47 | 0.23 | +0.77% |
| WisdomTree True Emerging Markets Fund (XC) | |||
| BNDX | 46.86 | 0.07 | +0.15% |
| Vanguard Total International Bond ETF (BNDX) | |||
| RNP | 18.53 | 0.01 | +0.05% |
| Cohen & Steers REIT and Preferred and Income Fund | |||
| TLDR | 25.01 | N/A | +0.02% |
| Laddered T-Bill ETF (TLDR) | |||
| BSMQ | 23.43 | N/A | N/A |
| Invesco BulletShares 2026 Municipal Bond ETF (BSMQ) | |||
A.I.dvisor indicates that over the last year, IVA has been loosely correlated with ABEO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then ABEO could also see price increases.
| Ticker / NAME | Correlation To IVA | 1D Price Change % | ||
|---|---|---|---|---|
| IVA | 100% | +2.89% | ||
| ABEO - IVA | 38% Loosely correlated | +0.40% | ||
| TVGN - IVA | 37% Loosely correlated | +1.23% | ||
| NKTX - IVA | 36% Loosely correlated | +0.59% | ||
| CABA - IVA | 35% Loosely correlated | +5.82% | ||
| SLDB - IVA | 34% Loosely correlated | -1.86% | ||
More | ||||